接受或不接受自体干细胞移植的套细胞淋巴瘤患者的晚期效应
这项基于瑞典淋巴瘤登记的人群研究纳入2000至2014年确诊的18至69岁套细胞淋巴瘤患者620例(其中247例接受HD-ASCT)及1:10匹配的健康对照,随访至2017年12月。与匹配对照相比,患者专科和医院就诊率显著更高,感染、呼吸和血液系统疾病相对风险尤其高。观察期内,接受与未接受HD-ASCT的患者之间这些并发症(包括继发肿瘤)的发生率无差异。多数患者死于淋巴瘤本身而非其他原因或治疗并发症。
要点
- 与匹配健康对照相比,套细胞淋巴瘤患者专科和医院就诊率显著更高。
- 患者感染、呼吸和血液系统疾病的相对风险尤其高。
- 观察期内接受与未接受HD-ASCT的患者并发症发生率无差异。
核心结论
- 多数治疗后医疗保健需求与淋巴瘤疾病本身相关,提示需要更有效的治疗选择。
- 多数患者死于淋巴瘤本身而非其他原因或治疗并发症。
研究设计与样本
- 基于瑞典淋巴瘤登记的人群研究,纳入2000至2014年确诊的18至69岁套细胞淋巴瘤患者620例(接受HD-ASCT者247例)及1:10匹配的健康对照。
- 通过国家患者登记和死因登记随访,从诊断或匹配后12个月至2017年12月。
- 使用负二项回归模型估计门诊就诊、住院和住院天数的发生率比。
主要发现
- 与匹配对照相比,套细胞淋巴瘤患者专科和医院就诊率显著更高。
- 套细胞淋巴瘤患者感染、呼吸和血液系统疾病的相对风险尤其高。
- 观察期内,接受与未接受HD-ASCT的患者之间这些并发症(包括继发肿瘤)的发生率无差异。
- 多数患者死于淋巴瘤本身而非其他原因或治疗并发症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Studies on late effects in patients with mantle cell lymphoma (MCL) are becoming increasingly important as survival is improving, and novel targeted drugs are being introduced. However, knowledge about late effects is limited. The aim of this population-based study was to describe the magnitude and panorama of late effects among patients treated with or without high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT). The study cohort included all patients with MCL, recorded in the Swedish Lymphoma Register, aged 18 to 69 years, diagnosed between 2000 and 2014 (N = 620; treated with HD-ASCT, n = 247) and 1:10 matched healthy comparators. Patients and comparators were followed up via the National Patient Register and Cause of Death Register, from 12 months after diagnosis or matching to December 2017. Incidence rate ratios of the numbers of outpatient visits, hospitalizations, and bed days were estimated using negative binomial regression models. In relation to the matched comparators, the rate of specialist and hospital visits was significantly higher among patients with MCL. Patients with MCL had especially high relative risks of infectious, respiratory, and blood disorders. Within this observation period, no difference in the rate of these complications, including secondary neoplasms, was observed between patients treated with and without HD-ASCT. Most of the patients died from their lymphoma and not from another cause or treatment complication. Taken together, our results imply that most of the posttreatment health care needs are related to the lymphoma disease itself, thus, indicating the need for more efficient treatment options.
引用
- Ekberg S, Smedby KE, Albertsson-Lindblad A, et al. Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation. Blood Adv. 2023. PMID: 35973196. doi:10.1182/bloodadvances.2022007241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。